

ΥΠΟΣΧΟΜΕΝΕΣ ΕΦΑΡΜΟΓΕΣ ΤΩΝ LASER ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ

Καρελιώτης Γ., Φυσικός Ιατρικής – Ακτινοφυσικός, Υ.Δ.

Εργαστήριο Οπτοηλεκτρονικής, Laser και Εφαρμογών τους – Σ.Ε.Μ.Φ.Ε. – Ε.Μ.Π.



24/11/2018

ΔΙΕΘΝΗΣ ΗΜΕΡΑ ΙΑΤΡΙΚΗΣ ΦΥΣΙΚΗΣ 2018

ΕΚΠΑΙΔΕΥΤΙΚΗ ΗΜΕΡΙΔΑ

Η ΧΡΗΣΗ ΤΩΝ LASERS ΣΤΗΝ ΙΑΤΡΙΚΗ. ΚΛΙΝΙΚΕΣ ΕΦΑΡΜΟΓΕΣ ΚΑΙ ΑΣΦΑΛΗΣ ΛΕΙΤΟΥΡΓΙΑ



Ιατρική Φυσική και Καρκίνος

Θεραπεία του καρκίνου

Ακτίνες Χ και γ

Αδρόνια

Φωτοδυναμική
Θεραπεία

Φωτοθερμική
Θεραπεία

Ιοντίζουσα & μη-ιοντίζουσα ακτινοβολία

Δοσιμετρία και Ακτινοπροστασία στην Ιατρική Φυσική


Φως και επιστήμες υγείας



Arthur Ashkin, Gérard Mourou and Donna Strickland

Βραβείο Νόμπελ
Φυσικής
2018

For the optical tweezers and their application to biological systems and for their method of generating high-intensity, ultra-short optical pulses”.




Niels Ryberg Finsen

Βραβείο Νόμπελ
Φυσιολογίας & Ιατρικής
1903

In recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation, whereby he has opened a new avenue for medical science

Φως και κλινική πράξη

Το φως χρησιμοποιείται στην ιατρική πράξη από την αρχαιότητα έως και σήμερα




1 στους 4 θανάτους στον δυτικό κόσμο οφείλεται στον καρκίνο



1930. London's Institute of Ray Therapy.
(FOX PHOTOS/GETTY IMAGES)

Στο μέλλον όμως;;



Τα 4.500 ετών οστά άνδρα από τη Σιβηρία που πέθανε από καρκίνο ¹



Μούμια άνδρα 2.250 ετών που πέθανε από καρκίνο του προστάτη ²

Φωτοθερμική Θεραπεία (PTT)

Laser-induced interstitial thermotherapy (LIIT)
Αξιοποιεί μη - ιοντίζουσα ακτινοβολία

$T \geq 43^{\circ}\text{C}$
 $\Delta t \geq 60 \text{ min}$

Θάνατος εντός 48 h ³

$P \approx 12 \text{ W}$
 $\Delta t \approx 2 - 8 \text{ min}^3$

Ενέργεια φωτονίων



Θερμότητα



Θερμική καταστροφή του όγκου - στόχου

Συνδυασμός με MRI
(MR Thermometry)



3D real - time χωρική
κατανομή της θερμότητας ⁴

Φωτοθερμική Θεραπεία (LIIT)

1971

Προτείνεται για 1^η φορά η
χρήση υπερθερμίας σε
ενδοκρανιακούς όγκους ⁵

Γλοιώματα ακτίνας > 1,4 cm ⁶



Κίνδυνος οιδήματος

Για $T > 50^{\circ} \text{C}$ έχουμε
αλλαγές των οπτικών
ιδιοτήτων ⁷

Μελέτες για εφαρμογή σε:

Θυρεοειδή ⁸

Μαστό ⁹

Ήπαρ ¹⁰

Υπολογισμός χρόνου
ακτινοβολήσης:

$$\Delta t = A \cdot \exp \left[\frac{E}{R} (T + 273) \right] ^4$$

Φωτοδυναμική Θεραπεία (PDT)


Μέθοδος αντιμετώπισης περιπτώσεων κακοήθειας (κυρίως)
Αξιοποιεί μη - ιοντίζουσα ακτινοβολία

3 βασικά στοιχεία

Φωτοευαισθητοποιός ουσία

Οξυγόνο

Φως (laser)



Φωτοδυναμική Θεραπεία (PDT)

1907

Ο Hermann von Tappeiner εισάγει τον όρο «Φωτοδυναμική Θεραπεία»¹¹


Ήδη από το 1978 η PDT χρησιμοποιείται πειραματικώς για δερματικούς καρκίνους με laser χρωστικών¹²

Μόλις το 1996 δίνεται έγκριση της FDA για χρήση της PDT στις Η.Π.Α.



Σήμερα εφαρμόζεται με έγκριση¹³ στον καρκίνο:

- του δέρματος (παγκοσμίως)
- της κεφαλής και του τραχήλου (Ευρώπη)
- του πνεύμονα (Ιαπωνία)
- του χοληφόρου πόρου (orphan status in EU/USA)




Φωτοδυναμική Θεραπεία Καρκίνος του χοληφόρου πόρου

Συνήθως έχει ταχύ ρυθμό
εξάπλωσης, επιβίωση 4 – 6 μήνες
και επιλέγονται παρηγορητικές
θεραπείες & τοποθέτηση stents


PDT

Επιβίωση 3 – 18,6 μήνες¹⁴

Κλινική μελέτη που τερματίστηκε
νωρίτερα λόγω πολύ μεγάλης
αποτελεσματικότητας της PDT...



Καρκίνος χοληφόρου πόρου πριν (αριστερά)
και 4 μήνες μετά την PDT (δεξιά)¹⁴



Ανατομία του εξωηπατικού χοληφόρου
πόρου (NCBI - NIH)

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT

Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study

MARIANNE E. J. ORTNER,¹ KAREL ČÁČEK,¹ FRIEDER BEHR,¹ JOCHEN LIEBETHUTH,¹ ULRICH MANDMANN,¹ DOMINIK HUSTER,¹ WILFRIED VODERHOLZER,² GUIDO SCHACHSCHAL,³ JOACHIM MOSSNER,⁴ and HERBERT LÖCHS¹

¹Institut für Gastroenterologie und Hepatologie, Centro medicum Universitätsklinikum, Lüneburg, Lüneburg; ²Treatment of Medicine II, University of Lüneburg, Lüneburg; ³Department of Medicine II, University of Lüneburg, Lüneburg; ⁴Department of Surgery and ⁵Gastroenterology, Hepatology, Endocrinology, Metabolism and Nutrition, Medical Faculty Charité, Humboldt University, Berlin, Germany; and ⁶Institute for Biostatistics and Epidemiology, University of Wuppertal, Wuppertal, Germany

See editorial on page 1526.

Background & aims: In nonresectable cholangiocarcinoma (NCC), photodynamic therapy (PDT) has a promising effect on nonresectable cholangiocarcinoma (NCC). This prospective, open-label, randomized, multicenter study with a group sequential design compared PDT in addition to stenting (group A) with stenting alone (group B) in patients with NCC. Methods: In patients with histologically confirmed cholangiocarcinoma, endoscopic or percutaneous stent placement was performed. Patients fulfilling inclusion criteria were randomized to group A (stenting and subcutaneous PDT) and group B (stenting alone). For PDT, Photofrin 2 mg/kg body wt was injected intravenously 2 days before intraluminal photocoagulation (wavelength, 630 nm; light dose, 180 J/cm²). Further treatments were performed in cases of residual tumor in the bile duct. The primary outcome parameter was survival time. Secondary outcome parameters were cholestasis and quality of life. Results: PDT resulted in prolongation of survival (group A, n = 20; median 600 days; group B, n = 18; P = .002) and quality of life. Conclusions: PDT, in addition to best supportive care, improves survival in patients with NCC. The study was terminated prematurely because PDT proved to be so superior to simple stenting treatment that further randomization was deemed unethical.

stenting, however, the prognosis is still dismal.^{11–13} It is particularly bad in centrally located patients with large tumors.¹⁴ Tumor resection^{15,16} and extension of the tumor in the bile ducts¹⁷ are further prognostic factors. In patients with advanced Bismuth type III and IV tumors,¹⁸ 30-day mortality rates between 50% and 45% and median survival times between 15 and 127 days^{19–21} have been reported. In the only randomized study, a median survival time of 95 days was obtained in patients with tumors >2 cm.²² Attempts to improve prognosis by adding chemotherapy to stenting have been largely unsuccessful.²³ It is controversial whether additional radiotherapy improves outcome.^{24–26}

Photodynamic therapy (PDT) has recently been described as a technically feasible method for the treatment of NCC.^{27–29} It involves administration of a nontoxic photosensitizer that is preferentially retained by neoplastic tissue. Following absorption of light energy transferred from the photosensitizer to molecular oxygen, resulting in tumor cell death.^{30–32} The NCC treatment photosensitizers with deep tissue penetration, such as hexamethylporphyrin derivatives or chlorin derivatives,^{33–35} are to be preferred to photosensitizers with only a superficial effect.³⁶

PDT with hexamethylporphyrin derivatives appeared to prolong survival of NCC in small uncontrolled trials.^{37–40} However, selection bias and the risk of adverse effects

Cholangiocarcinoma is a highly rare diagnosed before liver transplantation occurs as a consequence of advanced disease. As a result, fewer than 50% of patients are suitable for curative surgical treatment. Because the results of palliative surgery in nonresectable cholangiocarcinoma (NCC) are disappointing,¹¹ biliary stenting is regarded as the palliative method of choice. Despite

© 2006 Blackwell Publishing Ltd, *Journal of Clinical Gastroenterology*, 40, 1525–1530
© 2006 The American Gastroenterological Association
0895-2875/06/401525-06
DOI: 10.1111/j.1572-0244.2006.01232.x

Φωτοδυναμική Θεραπεία Καρκίνος του ήπατος

Br. J. Cancer (1986), **54**, 43-52

Photodynamic therapy with porphyrin and phthalocyanine sensitisation: Quantitative studies in normal rat liver

S.G. Bown, C.J. Tralau, P.D. Coleridge Smith, D. Akdemir & T.J. Wieman

Rayne Institute, Faculty of Clinical Sciences, University College, London, UK.

Summary. Selective sensitisation of malignant tumours to monochromatic light photodynamic therapy (PDT) is a promising approach to cancer treatment, but current sensitisers are unsatisfactory and the parameters controlling effects produced in normal and neoplastic tissue are poorly understood. To measure the effects in a tumour-bearing rat model, the effects of PDT were studied in normal rats following systemic sensitisation with haematoporphyrin derivative (HpD) and a new sensitiser, a sulphated aluminium phthalocyanine (AlSPc) using light from an Argon pumped tunable dye laser. Damage from PDT (dominant at 100 mW laser power) could be distinguished from that due to local hyperthermia (dominant at 400 mW). For both sensitisers, the extent of PDT necrosis increased with the applied light energy and was abolished by occluding the hepatic blood flow during therapy. With HpD, the extent of PDT necrosis was maximum with only a few hours between sensitisation and therapy, and was not detectable when this interval was increased to a week. With AlSPc, the extent of necrosis in liver changed little with sensitisation times from 1 h to 1000 h (6 weeks), and declined slowly thereafter, matching the amount of AlSPc measurable by alkali extraction, although prolonged photosensitisation was not seen with AlSPc in muscle. Less cutaneous photosensitisation was seen with AlSPc than with HpD. AlSPc is easier to produce and handle than HpD, has a more appropriate strong absorption peak (at 675 nm) and from these results, warrants further study as a photosensitiser for PDT.

Photodynamic therapy (PDT, previously referred to as photoradiation therapy or PRT) has attracted interest in the last few years as a new technique with the potential for selective local destruction of malignant tumours. It is based on the systemic administration of sensitising drugs which may be retained selectively in tumours relative to the surrounding normal tissue and can be activated by light to produce a local cytotoxic effect. Certain aspects of the biological processes involved have been studied in detail, but there are many aspects of the response of both normal and neoplastic tissue to PDT that must be explored before it will be possible to assess what role it may have in the treatment of human disease (Doiron & Gomer, 1984).

Most work has used haematoporphyrin derivative (HpD) as the sensitising agent as this has been shown to provide selective fluorescence in a wide range of human cancers (Gregorie *et al.*, 1968). *In vitro* studies show that HpD is taken up by both normal and neoplastic cell lines in tissue culture and that cell death (probably due to membrane lysis) can be produced by exposure of sensitised cells to light of a wavelength matched to an absorption peak of HpD (usually 630 nm).

Correspondence: S.G. Bown
Received 13 November 1985; and in revised form, 5 March 1986.

© The Macmillan Press Ltd., 1986

Unsensitised cells survive the same light dose. However, there is no major difference in the responses of normal and neoplastic cells (Christensen *et al.*, 1981). Nevertheless, studies on transplanted mammary carcinomas in mice suggest that within the tumours, HpD is retained in the vascular stroma, not in individual malignant cells, and that the primary effect of light is to cause a vascular shutdown, necrosis of tumour cells occurring secondary to this (Bugelski *et al.*, 1981, Star *et al.*, 1984) which may explain the selectivity seen in tumours which is not apparent in tissue culture studies. This hypothesis is supported by experiments in which tumour cells were transplanted to tissue culture immediately after phototherapy and grew normally, whereas those transplanted 12 h later were not viable (Henderson *et al.*, 1985a). Studies on the regrowth of small transplanted tumours in mice after PDT show that with certain treatment parameters, tumours can be cured and the animals have a normal lifespan (Dougherty *et al.*, 1975). However, few of these reports have looked at more than a small number of the parameters involved and how varying these influences the biological effect. There are no histological studies to follow the effects through from the time of phototherapy until healing is complete, and no studies of what happens at the junction of normal and neoplastic tissue, although this is the most important region when considering

Από το 1986 μελετάται η
χρησιμότητα της PDT σε
ηπατικούς όγκους αρουραίων ¹⁵

Η αποτελεσματικότητα περιοριζόταν
από τις φωτοευαίσθητες ουσίες και
την έλλειψη γνώσης των
παραμέτρων τους

Από το 1999 φαίνεται η
αποτελεσματικότητα της PDT σε
ηπατικούς όγκους ¹⁶

Πλήρης ύφεση του όγκου στο 87%
των πειραματόζων

Φωτοδυναμική Θεραπεία Καρκίνος του πνεύμονα


Μελετάται από το 1984^{17,18}

Συνήθως με χρήση Photofrin
(Φωτοευαισθητοποιητής 1^{ης} γενιάς)

Talaporfin Sodium (TS)
(Φωτοευαισθητοποιητής 2^{ης} γενιάς)



Διεγείρει την αντίδραση του
ανοσοποιητικού συστήματος



PDT σε καρκίνο του πνεύμονα. 6 μήνες μετά πλήρης
υποχώρηση του όγκου¹⁹.

MV 6401
(Φωτοευαισθητοποιητής 2^{ης} γενιάς)




Επιδρά στη νεοαγγείωση

Πού έγκειται η δυσκολία;

Symbol	Definition
β (μM)	Oxygen quenching threshold concentration $\frac{k_4 + k_8[A]}{k_2}$
δ (μM)	Low concentration correction
η ($\text{cm}^2 \text{mW}^{-1} \text{s}^{-1} \mu\text{M}$)	Hypoxic reaction consumption rate $\Phi_i \frac{\epsilon}{h\nu} \frac{k_8[A]}{k_2}$
ξ ($\text{cm}^2 \text{mW}^{-1} \text{s}^{-1}$)	Specific oxygen consumption rate $\xi = \xi_{II} + \xi_I = S_{\Delta} \Phi_i \frac{\epsilon}{h\nu} + S_I \Phi_i \frac{\epsilon}{h\nu}$
σ (μM^{-1})	Specific photobleaching ratio $\sigma = (\xi_{II}\sigma_{II} + \xi_I\sigma_I)/\xi$ where $\sigma_{II} = k_{12}\tau_{\Delta}$ and $\sigma_I = k_{11}\tau_s$
g ($\mu\text{M s}^{-1}$)	Macroscopic maximum oxygen supply rate
ϵ ($\text{cm}^{-1} \mu\text{M}^{-1}$)	Photosensitizer extinction coefficient
τ_f (s)	Fluorescence lifetime $\frac{1}{k_3 + k_5}$
τ_{Δ} (s)	Singlet oxygen lifetime $\frac{1}{k_{12}([S_0] + \delta) + k_6 + k_{72}[A]}$
τ_s (s)	Superoxide (ROS) lifetime $\frac{1}{k_{11}([S_0] + \delta) + k_{71}[A]}$
τ_t (s)	Triplet state lifetime $\frac{1}{k_4 + k_2[{}^3\text{O}_2] + k_8[A]}$
$[A]$ (μM)	Singlet oxygen receptors, considered a constant during PDT because it is too large to be changed during PDT.
S_{Δ}	Fraction of triplet-state photosensitizer- ${}^3\text{O}_2$ reactions to produce ${}^1\text{O}_2$
S_I	Fraction of triplet-state photosensitizer reactions involved in Type I reactions
S_{NL}	Fraction of triplet state photosensitizer reactions that are non-luminescent $S_{\Delta} + S_I + S_{NL} = 1$
Φ_{Δ}	Singlet oxygen quantum yield $S_{\Delta} \frac{k_5}{k_3 + k_5}$
Φ_{ROS}	Superoxide anion quantum yield $S_I \frac{k_5}{k_3 + k_5}$
Φ_f	Fluorescence quantum yield $\frac{k_5}{k_3 + k_5} \frac{k_{3R}}{k_3}$, where k_{3R} is fluorescence radiative decay rate between S_1 and S_0
Φ_t	Triplet quantum yield $\frac{k_5}{k_3 + k_5}$

Μεγάλο πλήθος παραμέτρων που πρέπει να ληφθούν υπόψη

Ιδιαίτερως πολύπλοκη η εξατομικευμένη δοσιμετρία ²¹




Μόνο 4 φωτοευαισθητοποιητές έχουν πάρει έγκριση και FDA και EMA ¹³

Πού έγκειται η δυσκολία;

Κάθε φωτοευαίσθητη ουσία έχει διαφορετική κορυφή απορρόφησης


~ 70...





Μεγάλη ποικιλία laser (με βάση το λ τους)

Πού έγκειται η δυσκολία;

Επενεργούμε μόνο όπου ακτινοβολούμε;



Σε αντίθεση με τις θεραπείες με ιοντίζουσα ακτινοβολία δεν υπάρχουν ευρέως αποδεκτά και πλήρη πρωτόκολλα



Συνδυαστικές Θεραπείες

Η χρήση νανοδομών ενισχύει σημαντικά το αποτέλεσμα της PTT και της PDT ^{22, 23, 24}

Πρόσφατες μελέτες για τη συνεργατική δράση νανοδομών – PTT – PDT ^{23, 25}

Νανοδομές με κορυφή απορρόφησης στο NIR



Αυξημένο βάθος διείσδυσης στους ιστούς

Μελέτες

- PTT + ακτινοθεραπεία ²⁶
- PDT + ακτινοθεραπεία ²⁷
- PDT + πυρηνική ιατρική ²⁸
-

Remember

Logic will get you from A to B. Imagination
will take you everywhere...

Albert Einstein

Αναφορές

- ¹ Oldest 'definite' case of human cancer discovered in 4,500-year-old human remains from Siberia. The Siberian Times 2014; Available from: <http://siberiantimes.com/science/casestudy/news/n0045-oldest-definite-case-of-human-cancer-discovered-in-4500-year-old-human-remains-from-siberia/>.
- ² Pringle, H. Mummy Has Oldest Case of Prostate Cancer in Ancient Egypt. 2011.
- ³ Sloan AE, Ahluwalia MS, Valerio-Pascua J, Manjila S, Torchia MG, Jones SE, Sunshine JL, Phillips M, Griswold MA, Clampitt M, Brewer C, Jochum J, Mc- Graw MV, Diorio D, Ditz G, Barnett GH: Results of the NeuroBlate System first-in-humans phase I clinical trial for recurrent glioblastoma. J Neurosurg 2013; 118: 1202–1219.
- ⁴ Karamelas, I. and A. E. Sloan , "Laser-induced interstitial thermotherapy of gliomas." Prog Neurol Surg, 2018, **32**: 14-26.
- ⁵ Sutton CH: Tumor hyperthermia in the treatment of malignant gliomas of the brain. Trans Am Neurol Assoc 1971; 96: 195–199.
- ⁶ Mohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, Tatter SB, Barnett GH, Leuthardt EC: The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. Cancer Med 2014; 3: 971–979.
- ⁷ Ritz, J.P., et al., *Continuous changes in the optical properties of liver tissue during laser-induced interstitial thermotherapy*. Lasers Surg Med, 2001. **28**(4): p. 307-12.
- ⁸ Papini E, Guglielmi R, Hosseim G, et al. Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: A potential therapeutic approach in patients at surgical risk. Thyroid, 2011,**21**(8):917-92
- ⁹ van Esser S, Stapper G, van Diest PJ, et al. Ultrasound-guided laser-induced thermal therapy for small palpable invasive breast carcinomas: a feasibility study. Ann Surg Oncol, 2009,**16**(8):2259-2263
- ¹⁰ Wiggermann P, Puls R, Vasilij A, et al. Thermal ablation of unresectable liver tumors: Factors associated with partial ablation and the impact on long-term survival. Med Sci Monit, 2012,**18**(2):CR88-CR92
- ¹¹ von Tappeiner, H. and A. Jodlbauer, Die sensibilisierende Wirkung fluoreszierender Substanzen. Gesamte Untersuchungen über die photodynamische Erscheinung. Leipzig: FCW Vogel, 1907.
- ¹² Kato, H., History of photodynamic therapy--past, present and future. Gan To Kagaku Ryoho, 1996. **23**(1): p. 8-15.
- ¹³ van Straten, D., et al., Oncologic photodynamic therapy: Basic principles, current clinical status and future directions. Cancers (Basel), 2017. **9**(2).
- ¹⁴ Cheon, Y., The role of photodynamic therapy for hilar cholangiocarcinoma. Vol. 25. 2010. 345-52.
- ¹⁵ Bown, S.G., et al., Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver. Br J Cancer, 1986. **54**(1): p. 43-52.
- ¹⁶ Rovers, J.P., et al., Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model. Br J Cancer, 1999. **81**(4): p. 600-8.
- ¹⁷ Balchum, O.J.; Doiron, D.R.; Huth, G.C. HpD photodynamic therapy for obstructing lung cancer. Prog. Clin. Biol. Res. 1984, **170**, 727–745.
- ¹⁸ Li, J.H.; Chen, Y.P.; Zhao, S.D.; Zhang, L.T.; Song, S.Z. Application of hematoporphyrin derivative and laser-induced photodynamical reaction in the treatment of lung cancer: A preliminary report on 21 cases. Lasers Surg. Med. 1984, **4**, 31–37.
- ¹⁹ Kidane, B., D. Hirpara, and K. Yasufuku, Photodynamic therapy in non-gastrointestinal thoracic malignancies. Int J Mol Sci, 2016. **17**(1).
- ²⁰ Kim, M.M., et al., On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling. Phys Med Biol, 2017. **62**(5): p. R1-r48.
- ²¹ Kareliotis, G., et al. "Assessment of singlet oxygen dosimetry concepts in photodynamic therapy through computational modeling." Photodiagnosis and Photodynamic Therapy, 2018, **21**: 224-233.
- ²² Shibu, E. S., et al., "Nanomaterials formulations for photothermal and photodynamic therapy of cancer." Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2013, **15**: 53-72.
- ²³ Wei, X., et al., "Combined photodynamic and photothermal therapy using cross-linked polyphosphazene nanospheres decorated with gold nanoparticles." ACS Applied Nano Materials, 2018 **1**(7): 3663-3672.
- ²⁴ Tang, X., et al. "Overcome the limitation of hypoxia against photodynamic therapy to treat cancer cells by using perfluorocarbon nanodroplet for photosensitizer delivery." Biochemical and Biophysical Research Communications, 2017, **487**(3): 483-487.
- ²⁵ Li, L., et al., "CuS nanoagents for photodynamic and photothermal therapies. Phenomena and possible mechanisms." Photodiagnosis and Photodynamic Therapy, 2017, **19**: 5-14.
- ²⁶ Li, P., et al., *Photo-thermal effect enhances the efficiency of radiotherapy using Arg-Gly-Asp peptides-conjugated gold nanorods that target αvβ3 in melanoma cancer cells*. Journal of nanobiotechnology, 2015. **13**: p. 52-52.
- ²⁷ Xu, J., J. Gao, and Q. Wei, *Combination of Photodynamic Therapy with Radiotherapy for Cancer Treatment*. Journal of Nanomaterials, 2016. **2016**: p. 7.
- ²⁸ Kharroubi Lakouas, D., et al., *Nuclear medicine for photodynamic therapy in cancer: Planning, monitoring and nuclear PDT*. Photodiagnosis Photodyn Ther, 2017. **18**: p. 236-243.

Ευχαριστώ για την προσοχή σας !

Ερωτήσεις






Φωτοδυναμική Θεραπεία Καρκίνος του οισοφάγου

1994

Έγκριση για χρήση της Photofrin –
PDT ως θεραπευτική αγωγή για
επιφανειακό καρκίνο του
οισοφάγου



PDT σε καρκίνο του οισοφάγου (Johns Hopkins Hospital Division of Gastroenterology & Hepatology)

96

Gastrointestinal Intervention 2015 4(2), 95-98

Table 1 Types of Photosensitizers for Esophageal Photodynamic Therapy

Class	Photosensitizer	Treatment wavelength (λ, nm)	Diagnostic fluorescence wavelength (λ, nm)	Comments
Porphyrins	Porfimer sodium; also HpD; DHE	630	665-690	Porfimer sodium excellent red light tissue penetration with risk of stricture and prolonged skin sensitivity (Photofrin; also Photosan)
	5-ALA, a precursor of endogenous porphyrins	630-635	525, 665-690	Limited tissue penetration (≤ 2 mm); less photosensitivity (Levulan; Metvix)
Chlorins	mTHPC; temoporfin	650-660 (red), 514 (green)	525	Highly selective, potent 514 (green) compound suitable for less powerful light sources. Approved in European Union, Norway and Iceland (Focan; Biolitec Pharma)
Porphyrins (porphyrin macromolecules)	Mono- <i>n</i> -tetraaryl chlorins e6 (NP65; talaporfin or LS11); tin- <i>etio</i> -purpurin (SnEt2)	660-665	675	Phase III study using LS11 for hepatoma activated with light emitting diode (LED) (Light Sciences Oncology, Bellevue, WA, USA)
Phthalocyanine	Silicon phthalocyanine (Pc4); aluminum disulfonated phthalocyanine (AISPc); chloroaluminum phthalocyanine tetrasulfonate (AIPc5)	675	610	Limited phototoxicity and limited clinical information hydrophobic compounds that are difficult to purify. Selective tumor retention, minimal dark and cutaneous photosensitivity and excellent photodynamic activity are expected (Photosens)
Benzoporphyrins	Benzoporphyrin derivative (BPD); benzoporphyrin derivative monoacid (BPDMA); diethylene glycol benzoporphyrin derivative (Lemuteporfin)	690	690	Rapid tumor accumulation; transient limited skin photosensitivity and prominent vascular effects produced approval for use in macular degeneration (Visudyne); new diethylene glycol functionalized chlorin-type photosensitizer*
Porphyrin-like compounds	Motexafin lutetium; lutetium texaphyrin	730-740	730-740	Rapid tissue uptake and clearance and tissue penetration; used for photochemical angioplasty (Antin, Lutin, Lu-Tex)
Phenophorbides: (tetrapyrrole) chlorophyll derivatives	2-[1-Hexyloxyethyl]-2-devinyl-pyrrolophorbide-a (HPPH)	680	680	Undergoing evaluations for use in esophageal, skin, and recurrent breast cancer (Photochlor)

Reused from the article of Gross and Wolfson (Gastrointest Endosc Clin N Am. 2010;20:35-53) with original copyright holder's permission. HpD, hematoporphyrin derivative; DHE, dihematoporphyrin ether; 5-ALA, 5-Aminolevulinic acid; mTHPC, m-tetrahydroxyphenylchlorin.

Laser με μήκη κύματος
στην περιοχή του ερυθρού